Tiegang Yi
- Molecular Biology
- Pharmacology top 5%
- Nephrology top 10%
- Pharmacology
- Complementary and alternative medicine top 10%
- Topics
- Chronic Kidney Disease and Diabetes (6 papers)Renal Diseases and Glomerulopathies (3 papers)Advanced Glycation End Products research (3 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Tiegang Yi
20 papers receiving 447 citations
Peers
Comparison fields: 5 of 85
- Molecular Biology 208
- Pharmacology 96
- Nephrology 69
- Pharmacology 63
- Complementary and alternative medicine 57
Countries citing papers authored by Tiegang Yi
This map shows the geographic impact of Tiegang Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiegang Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiegang Yi more than expected).
Fields of papers citing papers by Tiegang Yi
This network shows the impact of papers produced by Tiegang Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiegang Yi. The network helps show where Tiegang Yi may publish in the future.
Co-authorship network of co-authors of Tiegang Yi
This figure shows the co-authorship network connecting the top 25 collaborators of Tiegang Yi. A scholar is included among the top collaborators of Tiegang Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiegang Yi. Tiegang Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | Artemether attenuates renal tubular injury by targeting mitochondria in adriamycin nephropathy mice. | 4 |
| 3 | 13 | |
| 4 | Niclosamide ethanolamine protects kidney in adriamycin nephropathy by regulating mitochondrial redox balance. | 12 |
| 5 | Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice. | 27 |
| 6 | 13 | |
| 7 | 27 | |
| 8 | 22 | |
| 9 | 62 | |
| 10 | 7 | |
| 11 | 13 | |
| 12 | 73 | |
| 13 | 24 | |
| 14 | 28 | |
| 15 | Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice. | 19 |
| 16 | 17 | |
| 17 | 17 | |
| 18 | 50 | |
| 19 | 8 | |
| 20 | 10 |
About Tiegang Yi
Tiegang Yi is a scholar working on Nephrology, Clinical Biochemistry and Pharmacology, having authored 20 papers that have together received 451 indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (6 papers), Renal Diseases and Glomerulopathies (3 papers) and Advanced Glycation End Products research (3 papers). The work is most often cited by research in Pharmacology (96 citations), Nephrology (69 citations) and Complementary and alternative medicine (57 citations). Tiegang Yi has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Jianping Chen, Hui-Lin Li, Pengxun Han, Mumin Shao, Huili Sun, Ziren Su, Shunmin Li, Wenjing Wang, Shunmin Li and Xuewen Yu. Their work appears in journals such as PLoS ONE, Scientific Reports and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.